Your basket is currently empty!
Axitinib is a tyrosine kinase inhibitor (TKI) which is a cancer growth blocker. Tyrosine kinase inhibitors work by blocking certain proteins called tyrosine kinases from acting on cells. Tyrosine kinases signal to cancer cells to grow. Axitinib blocks different types of tyrosine kinase and is called a multi kinase inhibitor. It stops cancer cells forming blood vessels, which the cancer needs in order to grow. This is called anti angiogenesis treatment. Avelumab with Axitinib was recommended by NICE in 2020 as an option for adults with untreated advanced renal cell carcinoma for use within the cancer drugs fund. The combination of axitinib and pembrolizumab is only available in Scotland.